- Home
- LRMR vs RCEL Comparison
LRMR vs RCEL Comparison
Compare LRMR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- RCEL
- Stock Information
- Founded
- LRMR N/A
- RCEL N/A
- Country
- LRMR United States
- RCEL United States
- Employees
- LRMR N/A
- RCEL N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- LRMR Health Care
- RCEL Health Care
- Exchange
- LRMR Nasdaq
- RCEL Nasdaq
- Market Cap
- LRMR 171.6M
- RCEL 161.5M
- IPO Year
- LRMR N/A
- RCEL N/A
- Fundamental
- Price
- LRMR $2.67
- RCEL $5.19
- Analyst Decision
- LRMR Strong Buy
- RCEL Strong Buy
- Analyst Count
- LRMR 7
- RCEL 4
- Target Price
- LRMR $18.86
- RCEL $16.50
- AVG Volume (30 Days)
- LRMR 1.1M
- RCEL 287.8K
- Earning Date
- LRMR 08-06-2025
- RCEL 08-07-2025
- Dividend Yield
- LRMR N/A
- RCEL N/A
- EPS Growth
- LRMR N/A
- RCEL N/A
- EPS
- LRMR N/A
- RCEL N/A
- Revenue
- LRMR N/A
- RCEL $71,661,000.00
- Revenue This Year
- LRMR N/A
- RCEL $57.29
- Revenue Next Year
- LRMR N/A
- RCEL $28.07
- P/E Ratio
- LRMR N/A
- RCEL N/A
- Revenue Growth
- LRMR N/A
- RCEL 41.35
- 52 Week Low
- LRMR $1.61
- RCEL $5.10
- 52 Week High
- LRMR $11.20
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- LRMR 56.20
- RCEL 29.07
- Support Level
- LRMR $2.60
- RCEL $5.10
- Resistance Level
- LRMR $3.02
- RCEL $6.33
- Average True Range (ATR)
- LRMR 0.25
- RCEL 0.32
- MACD
- LRMR 0.01
- RCEL 0.02
- Stochastic Oscillator
- LRMR 51.35
- RCEL 6.10
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.